Assessment of verify now P2Y12 assay accuracy in evaluating clopidogrel-induced platelet inhibition

Therapeutic Drug Monitoring

Volumn 30, Issue 3, 2008, Pages 372-378

  Lordkipanidzé, Marie ^a,b   Pharand, Chantal ^a,b   Nguyen, Thuy Anh ^a,b   Schampaert, Erick ^a,b   Diodati, Jean G ^a,b,c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b Division of Cardiology   (Canada)

^c HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

Clopidogrel; Inhibitory response; Platelet aggregation; VerifyNow P2Y12

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; PLACEBO; PURINERGIC P2Y12 RECEPTOR; THROMBIN RECEPTOR ACTIVATING PEPTIDE; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; PEPTIDE FRAGMENT; PROSTAGLANDIN E1; PURINERGIC P2 RECEPTOR; THROMBIN RECEPTOR PEPTIDE SFLLRNP; TICLOPIDINE;

ACCURACY; ADULT; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG DETERMINATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MONITORING; DRUG SCREENING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POINT OF CARE TESTING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; DRUG EFFECT; EVALUATION; HOSPITAL INFORMATION SYSTEM; METABOLISM; PROSPECTIVE STUDY; SAMPLE SIZE;

ADENOSINE DIPHOSPHATE; ADULT; ALPROSTADIL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PEPTIDE FRAGMENTS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POINT-OF-CARE SYSTEMS; PROSPECTIVE STUDIES; RECEPTORS, PURINERGIC P2; SAMPLE SIZE; TICLOPIDINE;

EID: 47249096142     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181757c59     Document Type: Article

References (22)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324: 71-86.
2. Patrono C, Coller B, FitzGerald GA, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:234S-264S.
3. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006;113:e166-286.
4. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol. 2005;45:1157-1164.
5. Michelson AD. Platelet function testing in cardiovascular diseases. Circulation. 2004;110:e489-493.
6. 12 assay. Product monograph. San Diego, CA: Accumetrics; 2006.
7. Pharand C, Nguyen TA, Lordkipanidzé M, et al. Prolonged prophylactic administration of high-dose clopidogrel before elective percutaneous coronary intervention is more effective than the standard 300 mg bolus in inhibiting platelet aggregation [Abstract]. Arterioscler Thromb Vasc Biol. 2007;27:e110.
8. Chatburn RL. Evaluation of instrument error and method agreement. Aana J. 1996;64:261-268.
9. van Werkum JW, van der Stelt CA, Seesing TH, et al. A head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention. J Thromb Haemost. 2006;4:2516-2518.
10. von Beckerath N, Pogatsa-Murray G, Wieczorek A, et al. Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness. Thromb Haemost. 2006;95: 910-911.
11. Malinin A, Pokov A, Spergling M, et al. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12 rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res. 2007;119: 277-284.
12. Samara WM, Bliden KP, Tantry US, et al. The difference between clopidogrel responsiveness and posttreatment platelet reactivity. Thromb Res. 2005;115:89-94.
13. Chung AW, Jurasz P, Hollenberg MD, et al. Mechanisms of action of proteinase-activated receptor agonists on human platelets. Br J Pharmacol. 2002;135:1123-1132.
14. Willoughby S, Holmes A, Loscalzo J. Platelets and cardiovascular disease. Eur J Cardiovasc Nurs. 2002;1:273-288.
15. Freedman JE. Molecular regulation of platelet-dependent thrombosis. Circulation. 2005;112:2725-2734.
16. Malinin A, Pokov A, Swaim L, et al. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol. 2006;28:315-322.
17. Bland JM, Altman DG. Applying the right statistics: analyses of measurement studies. Ultrasound Obstet Gynecol. 2003;22:85-93.
18. Hochholzer W, Trenk D, Frundi D, et al. Whole blood aggregometry for evaluation of the antiplatelet effects of clopidogrel. Thromb Res. 2007; 119:285-291.
19. Behan MW, Fox SC, Heptinstall S, et al. Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes. Platelets. 2005;16:73-80.
20. Labarthe B, Theroux P, Angioi M, et al. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J Am Coll Cardiol. 2005;46:638-645.
21. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49:1505-1516.
22. Mani H, Toennes SW, Linnemann B, et al. Determination of clopidogrel main metabolite in plasma: a useful tool for monitoring therapy? Ther Drug Monit. 2008;30:84-89.